Home
/ Cybin
/ Competitors

Cybin Competitors and Similar CompaniesClear all

Cybin's competitors and similar companies include Lundbeck, Taejoon, Jubilant Radiopharma and Almac Group.

	Cybin Cybin is a biopharmaceutical company that focuses on developing psychedelic-based therapeutics.	Lundbeck H. Lundbeck is a pharmaceutical company specializing in brain diseases.	Taejoon Taejoon is a pharmaceutical company.	Jubilant Radiopharma Jubilant Radiopharma (also known as Jubilant DraxImage) is a company that provides pharmaceutical solutions.	Almac Group Almac Group is a company that provides a range of services across the drug development lifecycle.
Founding Date	Founding Date 2019	Founding Date 1915	Founding Date 1978	Founding Date 1955	Founding Date 2002
Type	Type Public	Type Public	Type Private	Type Subsidiary	Type Subsidiary
Tags	Tags Healthcare drug development medical diagnostics mental health pharma rehabilitation	Tags Healthcare medical diagnostics mental health pharma	Tags Healthcare drug development medical diagnostics pharma	Tags Healthcare drug development medical diagnostics pharma	Tags Healthcare chemicals clinical research drug development pharma
Locations	Locations Toronto, CA HQ Dublin, IE	Locations København, DK HQ Buenos Aires, AR North Ryde, AU Wien, AT Bruxelles, BE Rio De Janeiro, BR Sofia, BG see more	Locations HQ	Locations Kirkland, CA HQ Noida, IN	Locations Craigavon, GB HQ Athlone, IE Dundalk, IE Minato City, JP Singapore, SG Alderley Edge, GB Belfast, GB see more
Employees	Employees 50	Employees 5,700	Employees 52	Employees 1381% increase	Employees 4,7021% increase
Valuation ($)	Valuation ($) 209.9 m	Valuation ($) 6.2 b	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) kr24.6b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) £735.1m (FY, 2021)
Cost of goods	Cost of goods N/A	Cost of goods kr2.7b (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods £474.7m (FY, 2021)
Gross profit	Gross profit N/A	Gross profit kr22b (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit £260.3m (FY, 2021)
Net income	Net income ($113.1m) (FY, 2025)	Net income kr3.2b (FY, 2025)	Net income N/A	Net income N/A	Net income £64.2m (FY, 2021)
Operating ⚠
Trademarks	Trademarks 24 (FY, 2023)	Trademarks 2.7 k (May, 2024)	Trademarks N/A	Trademarks N/A	Trademarks N/A